Turning Point Brands reports Q3 2026 earnings with rapid Modern Oral growth and lower adjusted EBITDA

Turning Point Brands posted third‑quarter 2026 net sales of $151.1 million, up 27% year over year, driven by Modern Oral nicotine‑pouch revenue that more than doubled to $74.4 million. Adjusted EBITDA fell 41% to $18.4 million as the company invested heavily in sales, marketing and distribution. Stoker’s segment sales rose 52% while Zig‑Zag sales declined 15.5%, and the firm reaffirmed its full‑year 2026 guidance for Modern Oral net sales of $260‑$270 million and adjusted EBITDA of $70‑$80 million.

The strong top‑line growth shows the Modern Oral segment is gaining market share, but the sharp drop in adjusted EBITDA highlights near‑term profitability pressure. The reaffirmed guidance and cash balance of $251 million give investors a view of future revenue upside and financial flexibility.

  • 1Net sales were $151.1 million, up 27.0% YoY.
  • 2Adjusted EBITDA declined 41% to $18.4 million.
  • 3Modern Oral net revenue reached $74.4 million, a 102.9% increase YoY.
  • 4Stoker’s segment net sales increased 52.0% to $113.8 million.
  • 5Zig‑Zag segment net sales fell 15.5% to $37.3 million.
  • 6The company repurchased 167,161 shares during the quarter.

Sources